NYXH Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.88
- P/S (TTM)
- 10.37
- EV/EBITDA
- -2.00
Profitability & growth
- ROE (TTM)
- -130.0%
- Operating margin
- -321.7%
- Revenue growth YoY
- 498.9%
- Dividend yield
- —
- Beta
- 0.89
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Nyxoah
Company profileNyxoah is a pioneering medical technology company specializing in innovative solutions for obstructive sleep apnea (OSA) treatment, primarily through its proprietary Genio system, which utilizes minimally invasive hypoglossal nerve stimulation techniques. Committed to clinical validation and extensive research, Nyxoah aims to significantly improve patient outcomes and quality of life for those suffering from OSA. By focusing on innovation within the sleep medicine sector and forming strategic partnerships, the company is well-positioned to capitalize on the increasing demand for effective…
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, BELGIUM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer